Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).

Key Inclusion Criteria:

- Subjects of childbearing potential (including female subjects who are post-menopausal
for less than 1 year) must practice effective contraception during the study and be
willing and able to continue contraception for 30 days after their last dose of study
treatment.

- Must have a confirmed diagnosis of RRMS according to the revised McDonald criteria
(2010) [Polman 2011]

Key Exclusion Criteria:

- History of or positive test result at Screening for:

- human immunodeficiency virus

- hepatitis C virus antibody

- hepatitis B infection

- Drug or alcohol abuse within 1 year prior to Screening.

- Prior treatment with any of the following:

- cladribine

- mitoxantrone

- total lymphoid irradiation

- alemtuzumab

- T-cell or T-cell receptor vaccination

- any therapeutic monoclonal antibody, with the exception of natalizumab or daclizumab

- Treatment with any of the following medications or procedures within 6 months prior to
Baseline (Day 1):

- DMF (given as Fumaderm®) or BG00012; enrollment will be limited to no more than 40
subjects (out of 200) with prior DMF exposure

- cyclosporine

- azathioprine

- methotrexate

- mycophenolate mofetil

- intravenous (IV) Ig

- plasmapheresis or cytapheresis

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply